Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

By J. Naidoo, D. Page, B. Li, L. Connell, K. Schindler, M. Lacouture, M. Postow, J. Wolchok. Annals of Oncology, 2016

641 citations recorded by the source corpus.

Subfields: Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/d88c6771bfe31cd71d4ec91a185a52cf4c317e6a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Wolchok
2. M. Postow
3. C. Robert
4. M. Hellmann
5. K. Kerr
6. M. Callahan
7. Georgina V. Long
8. J. Haanen

Citations in the corpus

• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Incidence of fatigue, of which the pathogenesis is poorly understood, across single drug studies, is 16%-37% for anti-PD-1 and 12%-24% for anti-PD-L1 [5].”
• Immune Checkpoint Inhibitors in Cancer Therapy (2022, background): “The toxicities corelated with PD-1/PD-L1 blockades were less severe compared to CTLA-4 inhibitors, and fatigue as the most common adverse event, occurring in 16–37% of patients receiving PD-1 inhibitor, and 12–24% of those who received PD-L1 inhibitor [147].”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “Incidence of fatigue, of which the pathogenesis is poorly understood, across single drug studies, is 16%-37% for anti-PD-1 and 12%-24% for anti-PD-L1 [5].”
• Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. (2017, background): “Patient feature Median age, years (range) 67 (36-89) Smoking status Current/former 24 (56) Never* 19 (44) Single agent v combination therapy Monotherapy 24 (56) Combination 19 (44) Underlying lung condition None 27 (63) Asthma 4 (9) Bronchiectasis 1 (2) COPD 1 (2) Interstitial lung disease 1 (2) Ple”
• PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome (2017, background): “MAbs can significantly reduce toxicity well within tolerable limits, while being able to shrink solid tumors, suppress advanced tumors and metastasis, and overall improve patient survival (Topalian et al., 2014; Naidoo et al., 2015).”